Canadian recommendations for the treatment of glioblastoma multiforme.
about
Expression of TYMS in lymph node metastasis from low-grade glioma.Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.Chemosensitized radiosurgery for recurrent brain metastases.Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.Restricted calorie ketogenic diet for the treatment of glioblastoma multiforme.Treatment for glioblastoma multiforme: current guidelines and Canadian practice.Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Acute ischemic stroke secondary to glioblastoma. A case reportPhase II study of PX-866 in recurrent glioblastoma.Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiformeSecondary gliosarcoma after the treatment of primary glioblastoma multiforme.Expression and mutation analysis of Cyclin A and Ki-67 in glioma and their correlation with tumor progression.Clinical target volume delineation in glioblastomas: pre-operative versus post-operative/pre-radiotherapy MRI.Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume.Gliosarcoma: A rare primary CNS tumor. Presentation of two casesTemozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.Quality appraisal of clinical practice guidelines on glioma.Calcineurin regulates nuclear factor I dephosphorylation and activity in malignant glioma cell lines.A case report of pseudoprogression followed by complete remission after proton-beam irradiation for a low-grade glioma in a teenager: the value of dynamic contrast-enhanced MRI.The effect of miR-7 on behavior and global protein expression in glioma cell lines.Does neurologic deterioration help to differentiate between pseudoprogression and true disease progression in newly diagnosed glioblastoma multiforme?Brain fatty acid-binding protein and omega-3/omega-6 fatty acids: mechanistic insight into malignant glioma cell migration.Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.Impact on Radiation Dose and Volume V57 Gy of the Brain on Recurrence and Survival of Patients with Glioblastoma Multiformae.Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?Topiramate induces acute intracellular acidification in glioblastoma.Unmet needs in the treatment of glioblastoma.Pro-apoptotic and anti-angiogenic properties of the α /β-thujone fraction from Thuja occidentalis on glioblastoma cells.Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression.Adjuvant Radiation Therapy and Temozolomide in Gliosarcoma: Is It Enough? Case Series of Seven Patients.Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.Nuclear Factor I Represses the Notch Effector HEY1 in Glioblastoma
P2860
Q30397716-CBDB469E-A422-4847-A2E9-9DE73DE5D7C3Q30579847-06686122-D6AA-4697-818C-1F1A40968C9DQ33402904-2815EBBB-8981-4DC7-BDC3-F802A5181112Q34073228-83597D2B-6AB8-4FED-A585-CA95CC57AEE8Q34344477-E4318117-FEBF-4060-BC3F-01C817204E97Q34359402-F9406DBB-4FE6-44F2-8768-13A0EC9F1538Q34362184-F4EB1471-0544-4C1C-83BC-8942F237115FQ34369582-213E21D8-B427-41BC-8A8C-3BD782F3E225Q34458889-70D8961E-AF10-45AA-840E-976F6DF031EAQ35027024-9F06E584-4B33-46F5-808F-74C8DF792894Q35731710-A2CA04BF-FB5E-4F1A-8D2F-1C62B65CF665Q35944627-C5CD1E4D-BFE9-45A9-BBAE-D47F38DF631CQ36325371-5B49FF5C-246F-486B-8519-B61BA4993C9EQ37037922-F1CCA01D-5BDA-403D-A47E-27B1514AEC85Q37392444-E1EFAC14-C82C-4B0E-953F-A8EB8D5BB50CQ37953862-7A8A5060-F8EB-48BD-9B65-7CF243502308Q38246969-964603F4-E4B6-4883-BA6F-0DDB28529C4BQ39128188-03C8A547-5F77-4234-A842-263DD4B57843Q39314240-8BEC31D6-A432-4EE5-9099-C8A6C8C1CA1BQ39436568-AC9A9F73-E999-478D-8702-75B6BE5E2D77Q41890870-A041EA62-E2F8-4543-8F6A-067B84182C4CQ41984462-BB0E9F70-90B8-4580-B80E-62FADE247D47Q46883877-F35080E3-7DEC-414A-A895-68063D4DFCE6Q47864874-D39319E4-C5A2-4687-969B-05B3EF11D1A8Q48097278-5504D2DA-DE24-4DC9-BC71-CE9D716C3D07Q48361647-85734B41-77EE-4255-87C3-7AF15113E128Q48614301-7AED8921-9A3F-4DD8-8430-0570ED7BAA74Q48888906-4AB0151E-1F8F-4CAA-BD31-34EC0D709D33Q49093936-9BBB4BE7-58C2-49E7-8F67-365FBBAFF5BAQ52571331-8FD0D3F2-746A-42BE-83C9-E812A80A6497Q53108051-7DF9C074-7813-40B7-84C5-025FAF042776Q58761337-B7E99E48-BE84-45C2-8EF2-C476A07743BD
P2860
Canadian recommendations for the treatment of glioblastoma multiforme.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Canadian recommendations for the treatment of glioblastoma multiforme.
@ast
Canadian recommendations for the treatment of glioblastoma multiforme.
@en
type
label
Canadian recommendations for the treatment of glioblastoma multiforme.
@ast
Canadian recommendations for the treatment of glioblastoma multiforme.
@en
prefLabel
Canadian recommendations for the treatment of glioblastoma multiforme.
@ast
Canadian recommendations for the treatment of glioblastoma multiforme.
@en
P2093
P2860
P356
P1433
P1476
Canadian recommendations for the treatment of glioblastoma multiforme
@en
P2093
B Thiessen
Canadian GBM Recommendations Committee
D Eisenstat
D Macdonald
R Del Maestro
P2860
P304
P356
10.3747/CO.2007.119
P577
2007-06-01T00:00:00Z